
Arcturus Therapeutics (ARCT) Stock Forecast & Price Target
Arcturus Therapeutics (ARCT) Analyst Ratings
Bulls say
Arcturus Therapeutics Holdings Inc. has demonstrated considerable potential for growth, particularly with the recent approval of its COVID-19 vaccine Kostaive in the European Union, which validates its innovative self-amplifying mRNA platform. The company's collaboration with CSL Seqirus to handle commercialization efforts reduces execution risk, thus providing a robust operational foundation for launching its products. Additionally, projected revenues exceeding $500 million within five years of product launch, coupled with enhancements in manufacturing capabilities and a favorable clinical efficacy profile, contribute to a positive long-term outlook for Arcturus's stock.
Bears say
Arcturus Therapeutics Holdings Inc. has faced a substantial downward revision in its revenue estimates, particularly for its Kostaive product, with projections for the 2026 COVID season falling from $156.4 million to just $11.8 million due to significantly lower expected vaccination demand in Japan. The company reported a net loss of $30 million for 4Q24 and a negative earnings per share of $1.11, which raises concerns about its ongoing operational viability given its high cash burn rate and reliance on the success of its lead mRNA asset. Key risks include potential safety issues with its candidates, the efficacy of its drugs in clinical trials, and challenges in securing sufficient funding, all of which contribute to a negative outlook on the stock's performance.
This aggregate rating is based on analysts' research of Arcturus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Arcturus Therapeutics (ARCT) Analyst Forecast & Price Prediction
Start investing in Arcturus Therapeutics (ARCT)
Order type
Buy in
Order amount
Est. shares
0 shares